← Eichor
Study identifier: NCT07284433 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

Condition: Lymphoma Diffuse Large B-cell · Leukemia and Lymphoma · Leukemia Relapse  ·  Sponsor: AvenCell Therapeutics, Inc.

PhasePhase 1/Phase 2
Planned participants178
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready to use, which can save time and reduce costs. It targets two proteins, CD19 and CD20, to lower the chance of relapse and uses gene editing to make it safer. The trial has three parts: first to find a safe dose, then to confirm it, and finally to test how well it works in patients with diffuse large B-cell lymphoma (DLBCL). Patients will get one infusion after chemotherapy to prepare their body. The main goal is to check safety and see how many patients have a complete response by Week 13. About 160 patients will take part, and researchers will follow them for up to 15 years.

This description comes directly from the study's public registry record.

Talk to the study team

Antje Warth, Dr.  ·  0493514466450  ·  avc-203-01@avencell.com

Markese Sanders  ·  617-941-7468  ·  avc-203-01@avencell.com

Always discuss trial participation with your own doctor first.

Locations (13)

University of ChicagoChicago, Illinois, United StatesNot Yet Recruiting
Northwestern UniversityEvanston, Illinois, United StatesNot Yet Recruiting
Brown University HealthProvidence, Rhode Island, United StatesNot Yet Recruiting
Sarah Cannon Research InstituteNashville, Tennessee, United StatesRecruiting
MD Anderson Cancer CenterHouston, Texas, United StatesNot Yet Recruiting
Universitätsklinikum UlmUlm, Baden-Wurttemberg, GermanyRecruiting
Universitätsklinikum ErlangenErlangen, Bavaria, GermanyRecruiting
Klinikum der Universität MünchenMunich, Bavaria, GermanyNot Yet Recruiting
Universitätsklinikum MarburgMarburg, Hesse, GermanyNot Yet Recruiting
Uniklinikum ErlangenEssen, North Rhine-Westphalia, GermanyNot Yet Recruiting
Universitätsklinikum DresdenDresden, Saxony, GermanyRecruiting
Charité Universitätsmedizin BerlinBerlin, GermanyRecruiting

+ 1 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07284433